Table 2.
Use of cardiovascular and antidiabetic drugs among patients who had antiobesity drugs dispensed (n = 36,772) and among the general population (n = 3,215,584) in NorPD in 2007
| Group | Cardiovascular drugsa | Antihypertensivesb | Lipid modifying agentsc | Drugs used in diabetesd | ||||
|---|---|---|---|---|---|---|---|---|
| SP | NorPD | SP | NorPD | SP | NorPD | SP | NorPD | |
| Total use | 36.7 | 27.5 | 33.4 | 22.5 | 17.0 | 12.4 | 9.4 | 4.1 |
| Use according to gender | ||||||||
| Men | 48.7 | 29.2 | 44.7 | 23.8 | 28.3 | 14.7 | 15.1 | 5.0 |
| Women | 33.6 | 26.1 | 30.5 | 21.4 | 14.1 | 10.5 | 7.9 | 3.4 |
| Use according to age (years) | ||||||||
| 0–29 | 4.6 | 2.0 | 4.0 | 0.7 | 0.8 | 0.2 | 3.9 | 0.8 |
| 30–59 | 32.1 | 20.5 | 28.5 | 15.0 | 13.0 | 8.3 | 8.1 | 3.4 |
| 60–99 | 73.7 | 65.7 | 69.3 | 57.6 | 41.9 | 32.0 | 17.6 | 8.8 |
Numbers given in percents
All differences in proportions (%) between SP and NorPD are statistic significant (P < 0.0005)
SP study population, NorPD Norwegian Prescription Database
aATC group C
bATC group C02, C03, C07, C08 and C09
cATC group C10
dATC group A10